for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
The Medical Letter
   [5 followers]  Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
     Published by The Medical Letter, Inc Homepage  [1 journal]   [SJR: 0.161]   [H-I: 15]
  • Drugs for Inflammatory Bowel Disease - The Medical Letter
    • Authors: admin
      Abstract: August 4, 2014 - Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease.
       
  • In Brief: Esomeprazole Strontium - The Medical Letter
    • Authors: admin
      Abstract: July 21, 2014 - The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium): treatment of gastroesophageal reflux disease (GERD), prevention of NSAID-induced gastric ulcers, eradication of Helicobacter pylori, and treatment of pathological hypersecretory conditions. It was first marketed in December 2013 as a branded drug (Esomeprazole Strontium) and a month later as a generic drug.Strontium is incorporated into bone. It is not recommended for use in children or during pregnancy...
       
  • In Brief: Low-Dose Indomethacin (Tivorbex) for Pain - The Medical Letter
    • Authors: admin
      Abstract: July 21, 2014 - The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain1 has now received approval from the FDA to market a lowdose oral formulation of indomethacin (Tivorbex) for the same indication. Tivorbex is available in 20- and 40-mg capsules; conventional immediate-release indomethacin capsules contain 25 mg and 50 mg of the drug.The rationale for this new product is the same as the one offered for Zorvolex: the drug is formulated as submicron...
       
  • Extended-Release Oxycodone and Acetaminophen (Xartemis XR) - The Medical
           Letter
    • Authors: admin
      Abstract: July 21, 2014 - The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen (Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release (Oxecta, and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin (Percodan, and others), acetaminophen (Percocet, and others), or ibuprofen (see Table 1).
       
  • Oral Propranolol (Hemangeol) for Infantile Hemangioma - The Medical Letter
    • Authors: admin
      Abstract: July 21, 2014 - The FDA has approved an oral solution of the nonselective beta-adrenergic blocker propranolol (Hemangeol – Pierre Fabre) for treatment of proliferating infantile hemangiomas.
       
  • Ceritinib (Zykadia) for Non-Small Cell Lung Cancer - The Medical Letter
    • Authors: admin
      Abstract: July 21, 2014 - Ceritinib (Zykadia – Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). It is the second tyrosine kinase inhibitor to be approved for ALK-positive metastatic NSCLC; crizotinib was the first. Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma.
       
  • A Responsive Neurostimulator Device (RNS System) for Epilepsy - The
           Medical Letter
    • Authors: admin
      Abstract: July 21, 2014 - The FDA has approved the use of a responsive neurostimulator device (RNS System – NeuroPace) for adjunctive treatment of adults with partial-onset seizures that are not controlled with ≥2 antiepileptic drugs and who have frequent and disabling seizures and no more than 2 epileptogenic foci.
       
  • Adult Immunization - Treatment Guidelines
    • Authors: admin
      Abstract: June 1, 2014 - Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014